Basal cell carcinoma (BCC) is the most common malignant neoplasm of humans. Rising
dramatically in incidence in North America, as likely reflects changing habits of the
population and a move from more northerly climes to the sunbelt of the Southern and
Southwestern United States, the incidence is surely to rise even higher in the future. The last
decade has seen significant advances in our understanding of BCC biology and novel
approaches to therapy, which hinge upon accurate diagnosis and subclassification by …